Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study

Area of Science:

• Oncology
• Dermatology

Background:

• Vismodegib is approved for advanced basal cell carcinoma (BCC) cases unsuitable for surgery or radiotherapy.
• Limited large-scale studies exist on vismodegib's real-world clinical application.

Purpose of the Study:

• To analyze the outcomes, including relapses and treatment resistance, of patients receiving vismodegib for advanced BCC in a multicenter, real-world setting.
• To evaluate the therapeutic management of treatment failures and relapses in advanced BCC patients on vismodegib.

Main Methods:

• A nationwide retrospective study involving 15 specialized centers.
• Data collected on patient/tumor characteristics, vismodegib efficacy, safety, relapse rates, and subsequent treatments.
• Multivariable logistic regression identified predictors of complete clinical response.

Main Results:

• The objective response rate (ORR) for 133 advanced BCC patients was 77.5%, with 45.9% achieving complete remission.
• Among 115 patients with long-term data, only 34% received further therapies or vismodegib rechallenge.
• 69% of patients with initial complete response remained recurrence-free; 30.7% relapsed. Rechallenge yielded a 55.5% ORR.

Conclusions:

• Vismodegib demonstrates efficacy in routine clinical practice for advanced basal cell carcinoma.
• The recurrence risk post-complete response appears lower than previously reported.
• Vismodegib rechallenge is feasible and effective for a significant proportion of patients.